The micronucleus assay using peripheral blood reticulocytes from mitomycin C- and cyclophosphamide-treated rats

Mutat Res. 1992 Feb-Mar;278(2-3):209-13. doi: 10.1016/0165-1218(92)90236-s.

Abstract

It used to be believed that the use of rat peripheral blood for the micronucleus assay would be difficult because micronucleated erythrocytes are captured and destroyed by the spleen quickly. We have applied an acridine orange (AO) supravital staining method to rat peripheral blood using AO-coated glass slides. Normal and splenectomized SD rats were treated once with mitomycin C (i.p.) or cyclophosphamide (p.o.), and 5 microliters of blood was collected at intervals from the tail vein between 0 and 72 h after treatment. For comparison, bone marrow cells were smeared conventionally 30 h after treatment. Although the frequencies of spontaneous and chemically induced micronucleated reticulocytes (MNRETs) from normal rats were lower on average in the highest dose group than those of splenectomized rats, the incidence of micronuclei among type I and II reticulocytes in normal rats at 48 h was almost identical to the incidence of RNA-containing erythrocytes with micronucleus in bone marrow. Thus, we suggest that rat peripheral reticulocytes can be used as target cells for the micronucleus assay.

MeSH terms

  • Acridine Orange
  • Animals
  • Cyclophosphamide / toxicity*
  • Dose-Response Relationship, Drug
  • Male
  • Micronucleus Tests / methods
  • Mitomycin / toxicity*
  • Mutagens / toxicity*
  • Rats
  • Rats, Inbred Strains
  • Reticulocytes / drug effects*
  • Splenectomy

Substances

  • Mutagens
  • Mitomycin
  • Cyclophosphamide
  • Acridine Orange